{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:33:10Z","timestamp":1793158390836,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prevention of TB is paramount to achieving elimination targets as recommended by the World Health Organization\u2019s action framework for low incidence countries striving to eliminate TB. Although the rates of TB in Canada are low, understanding the latent TB infection (LTBI) cascade is paramount to identifying gaps in care and treatment barriers, thereby increasing the effectiveness of preventive strategies. The purpose of this study was to examine the LTBI cascade of care and identify barriers to treatment completion in adults referred from primary care to a regional tertiary care TB clinic in Ottawa, Canada.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Electronic medical records between January 2010 and December 2016 were reviewed retrospectively and an LTBI cascade of care was constructed from The Ottawa Hospital TB clinic and surrounding primary care clinics. A cohort of 2207 patients with untreated LTBI was used to ascertain the associations between demographic and clinical factors for both treatment non-initiation and non-completion using log-binomial univariable and multivariable regression models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 2207 patients with untreated LTBI who were seen in the clinic during the study period, 1771 (80.2%) were offered treatment, 1203 (67.9% of those offered) started treatment, and 795 (66.1% of those started) completed treatment. In multivariable analysis, non-initiation of treatment was associated with older age (adjusted risk ratio [aRR] 1.06 per 5-year increase, 95% CI: 1.03\u20131.08) and female gender (aRR 1.28, 95% CI: 1.11\u20131.47). Non completion of treatment was associated with referral from the TB Clinic back to the primary care team following initial consult (aRR 1.62, 95% CI: 1.35\u20131.94) and treatment with the standard of 9\u2009months of Isoniazid (9H) compared to 4\u2009months of Rifampin (4R) (aRR 1.45, 95% CI:1.20\u20131.74).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>LTBI treatment completion was significantly decreased among patients who were referred back to primary care from the TB clinic. The 4R regimen resulted in more people completing LTBI treatment compared to 9H in keeping with a recently published RCT. Improved education, communication, and collaboration between tertiary care TB clinics and primary care teams may improve treatment completion rates and address the TB burden in low incidence communities in Canada.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-021-10733-9","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T18:02:36Z","timestamp":1621620156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Seven-year retrospective study understanding the latent TB infection treatment cascade of care among adults in a low incidence country"],"prefix":"10.1186","volume":"21","author":[{"given":"K.","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zwerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Van Dyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mulpuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Alsdurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. G.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"10733_CR1","volume-title":"Global Tuberculosis Report","author":"Organization WH","year":"2020","unstructured":"Organization WH. Global Tuberculosis Report. 2020."},{"key":"10733_CR2","unstructured":"Organization GWH. Global Tuberculosis Report 2019. Executive Summary. 2019 17 October 2019. Contract No.: WHO\/CDS\/TB\/2019.15."},{"issue":"10","key":"10733_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002152","volume":"13","author":"RM Houben","year":"2016","unstructured":"Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical Modelling. PLoS Med. 2016;13(10):e1002152.","journal-title":"PLoS Med"},{"issue":"10","key":"10733_CR4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S2213-2600(16)30275-2","volume":"4","author":"The Lancet Respiratory M","year":"2016","unstructured":"The Lancet Respiratory M. Focus on latent tuberculosis. Lancet Respir Med. 2016;4(10):763.","journal-title":"Lancet Respir Med"},{"issue":"2\u20133","key":"10733_CR5","first-page":"67","volume":"45","author":"M LaFreniere","year":"2019","unstructured":"LaFreniere M, Hussain H, He N, McGuire M. Tuberculosis in Canada: 2017. Can Commun Dis Rep. 2019;45(2\u20133):67\u201374.","journal-title":"Can Commun Dis Rep"},{"issue":"22","key":"10733_CR6","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMra1405427","volume":"372","author":"H Getahun","year":"2015","unstructured":"Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127\u201335.","journal-title":"N Engl J Med"},{"issue":"4","key":"10733_CR7","first-page":"555","volume":"60","author":"International Union Against Tuberculosis Committee on Prophylaxis","year":"1982","unstructured":"International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982;60(4):555\u201364.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"10733_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12879-017-2377-x","volume":"17","author":"C Pease","year":"2017","unstructured":"Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17(1):265.","journal-title":"BMC Infect Dis"},{"issue":"23","key":"10733_CR9","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155\u201366.","journal-title":"N Engl J Med"},{"issue":"7","key":"10733_CR10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1503\/cmaj.060124","volume":"175","author":"K Khan","year":"2006","unstructured":"Khan K, Campbell A, Wallington T, Gardam M. The impact of physician training and experience on the survival of patients with active tuberculosis. CMAJ. 2006;175(7):749\u201353.","journal-title":"CMAJ."},{"issue":"12","key":"10733_CR11","first-page":"1449","volume":"18","author":"A Rubinowicz","year":"2014","unstructured":"Rubinowicz A, Bartlett G, MacGibbon B, Greenaway C, Ronald L, Munoz M, et al. Evaluating the role of primary care physicians in the treatment of latent tuberculosis: a population study. Int J Tuberc Lung Dis. 2014;18(12):1449\u201354.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"10733_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5588\/ijtld.17.0027","volume":"21","author":"MJ Reid","year":"2017","unstructured":"Reid MJ, Goosby E. Lessons learned from the HIV care cascade can help end TB. Int J Tuberc Lung Dis. 2017;21(3):245\u20136.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"11","key":"10733_CR13","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","volume":"16","author":"H Alsdurf","year":"2016","unstructured":"Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269\u201378.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10733_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002754","volume":"16","author":"R Subbaraman","year":"2019","unstructured":"Subbaraman R, Nathavitharana RR, Mayer KH, Satyanarayana S, Chadha VK, Arinaminpathy N, et al. Constructing care cascades for active tuberculosis: a strategy for program monitoring and identifying gaps in quality of care. PLoS Med. 2019;16(2):e1002754.","journal-title":"PLoS Med"},{"issue":"6","key":"10733_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.14745\/ccdr.v40i06a04","volume":"40","author":"M Gale-Rowe","year":"2014","unstructured":"Gale-Rowe M, Menzies D, Sutherland J, Wong T. Chapter A. Highlights of the new 7th edition of the Canadian tuberculosis standards. Can Commun Dis Rep. 2014;40(6):113\u20136.","journal-title":"Can Commun Dis Rep"},{"issue":"5","key":"10733_CR16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","volume":"379","author":"D Menzies","year":"2018","unstructured":"Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440\u201353.","journal-title":"N Engl J Med"},{"issue":"5","key":"10733_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1086\/422995","volume":"39","author":"AS Gershon","year":"2004","unstructured":"Gershon AS, McGeer A, Bayoumi AM, Raboud J, Yang J. Health care workers and the initiation of treatment for latent tuberculosis infection. Clin Infect Dis. 2004;39(5):667\u201372.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10733_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1378\/chest.09-0394","volume":"137","author":"CR Horsburgh Jr","year":"2010","unstructured":"Horsburgh CR Jr, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010;137(2):401\u20139.","journal-title":"Chest."},{"issue":"4","key":"10733_CR19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.5588\/ijtld.12.0697","volume":"17","author":"PW Colson","year":"2013","unstructured":"Colson PW, Hirsch-Moverman Y, Bethel J, Vempaty P, Salcedo K, Wall K, et al. Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada. Int J Tuberc Lung Dis. 2013;17(4):473\u20139.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"2","key":"10733_CR20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/cid\/ciz817","volume":"71","author":"MD Swift","year":"2020","unstructured":"Swift MD, Molella RG, Vaughn AIS, Breeher LE, Newcomb RD, Abdellatif S, et al. Determinants of latent tuberculosis treatment acceptance and completion in healthcare personnel. Clin Infect Dis. 2020;71(2):284\u201390.","journal-title":"Clin Infect Dis"},{"key":"10733_CR21","volume":"11","author":"Q Liu","year":"2014","unstructured":"Liu Q, Abba K, Alejandria MM, Sinclair D, Balanag VM, Lansang MA. Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment. Cochrane Database Syst Rev. 2014;11:CD006594.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10733_CR22","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","volume":"380","author":"S Swindells","year":"2019","unstructured":"Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of Rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380(11):1001\u201311.","journal-title":"N Engl J Med"},{"issue":"19","key":"10733_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.15585\/mmwr.mm6819a3","volume":"68","author":"LE Sosa","year":"2019","unstructured":"Sosa LE, Njie GJ, Lobato MN, Bamrah Morris S, Buchta W, Casey ML, et al. Tuberculosis screening, testing, and treatment of U.S. health care personnel: recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morb Mortal Wkly Rep. 2019;68(19):439\u201343.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"10733_CR24","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1183\/13993003.01047-2015","volume":"46","author":"M Sester","year":"2015","unstructured":"Sester M, van Crevel R, Leth F, Lange C. Numbers needed to treat to prevent tuberculosis. Eur Respir J. 2015;46(6):1836\u20138.","journal-title":"Eur Respir J"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-10733-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-021-10733-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-10733-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T18:05:50Z","timestamp":1621620350000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-021-10733-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10733"],"URL":"https:\/\/doi.org\/10.1186\/s12889-021-10733-9","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"25 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the Ottawa Health Sciences Network Research Ethics Board. All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was waived by the Ottawa Health Science Network Research Ethics Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable for this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"964"}}